<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1349">
  <stage>Registered</stage>
  <submitdate>26/10/2006</submitdate>
  <approvaldate>26/10/2006</approvaldate>
  <nctid>NCT00393393</nctid>
  <trial_identification>
    <studytitle>Effectiveness Study of Hylan G-F 20 to Preserve Cartilage in Osteoarthritis of the Knee</studytitle>
    <scientifictitle>A Single-Blind Prospective Parallel Control Group Pilot Study to Assess the Effect of Hylan G-F 20 (Synvisc) Supplementation on Cartilage Preservation in Osteoarthritis of the Knee</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>05-11-07-05</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - intra-articular injection of Hylan G-F 20

Treatment: drugs: intra-articular injection of Hylan G-F 20


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Cartilage volume as assessed by magnetic resonance imaging</outcome>
      <timepoint />
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  grade 2 or 3 osteoarthritis knee age 18 - 80 pain score VAS &gt;39 mm on 100mm scale</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  surgery in prior 12 months significant valgus deformity recent trauma use of opioid
             analgesia unstable medical condition recent corticosteroid injection morbid obesity</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Emeritus Research - Malvern</hospital>
    <postcode>3144 - Malvern</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Cabrini Medical Centre</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Genzyme, a Sanofi Company</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>That Hylan G-F 20 may act to protect cartilage from the expected degree of degradation over a
      12 month period in subjects with moderate to marked osteoarthritis of the knee</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00393393</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>stephen hall, MBBS, FRACP</name>
      <address>Cabrini Medical Centre</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>stephen hall, MBBS, FRACP</name>
      <address />
      <phone>613 9509 6166</phone>
      <fax />
      <email>drshall@ozemail.com.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>